Research status and progress of the RNA or protein biomarkers for prostate cancer

: Prostate cancer is a kind of male malignancy. Recently, a large number of studies have reported many potential biomarkers for the diagnosis and prognosis of prostate cancer. In this literature review, we have collected a number of potential biomarkers for prostate cancer reported in the last 5 years. Among them, some are undergoing Phase III clinical trials, and others have been approved by the US Food and Drug Administration. However, most are still in the period of basic research. The review will contribute to future research to find the biomarkers to guide clinicians to make personalized treatment decisions for each prostate cancer patient. Men have a unique malignancy, prostate cancer. Prostate cancer can be dangerous to men. Doctors and scientists have done a lot of research to detect prostate cancer. In this article, we have summarized the suggestive substances found over the years. Doctors can tell if a patient has prostate cancer by examining these substances. Some of these substances are valuable and some of them are in experiment stages. We put them all together in order to better serve doctors and patients, to enable them to know which substances can help us identify prostate cancer.

[1]  Chunjiao Song,et al.  Predictive significance of TMRPSS2-ERG fusion in prostate cancer: a meta-analysis , 2018, Cancer Cell International.

[2]  G. Guelfi,et al.  Next Generation Sequencing of urine exfoliated cells: an approach of prostate cancer microRNAs research , 2018, Scientific Reports.

[3]  Shuanke Wang,et al.  Long Noncoding RNA SChLAP1 Accelerates the Proliferation and Metastasis of Prostate Cancer via Targeting miR-198 and Promoting the MAPK1 Pathway , 2018, Oncology research.

[4]  S. Hanash,et al.  Baseline and longitudinal plasma caveolin‐1 level as a biomarker in active surveillance for early‐stage prostate cancer , 2018, BJU international.

[5]  Chunjiao Song,et al.  The potential of microRNAs as human prostate cancer biomarkers: A meta‐analysis of related studies , 2017, Journal of cellular biochemistry.

[6]  K. D. Sørensen,et al.  Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis , 2017, International journal of molecular sciences.

[7]  Q. Hu,et al.  TRAF2 is a Valuable Prognostic Biomarker in Patients with Prostate Cancer , 2017, Medical Science Monitor.

[8]  J. Kench,et al.  A prospective multicentre phase III validation study of AZGP1 as a biomarker in localized prostate cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Jianmin Wang,et al.  Lipid quantification by Raman microspectroscopy as a potential biomarker in prostate cancer. , 2017, Cancer letters.

[10]  Mutsushi Yamasaki,et al.  Hypoxia-induced angiopoietin-like protein 4 as a clinical biomarker and treatment target for human prostate cancer. , 2017, Oncology reports.

[11]  D. Amadori,et al.  Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  M. Boutros,et al.  Database-augmented Mass Spectrometry Analysis of Exosomes Identifies Claudin 3 as a Putative Prostate Cancer Biomarker * , 2017, Molecular & Cellular Proteomics.

[13]  Wei Wei,et al.  MiR‐1, a Potential Predictive Biomarker for Recurrence in Prostate Cancer After Radical Prostatectomy , 2017, The American journal of the medical sciences.

[14]  Yan-bo Chen,et al.  The function of oxytocin: a potential biomarker for prostate cancer diagnosis and promoter of prostate cancer , 2017, Oncotarget.

[15]  Yi-Xiang Liao,et al.  Epidermal Growth Factor-Containing Fibulin-Like Extracellular Matrix Protein 1 (EFEMP1) Acts as a Potential Diagnostic Biomarker for Prostate Cancer , 2017, Medical science monitor : international medical journal of experimental and clinical research.

[16]  G. Guelfi,et al.  Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role , 2016, OncoTargets and therapy.

[17]  J. López-Miranda,et al.  Ghrelin O-acyltransferase (GOAT) enzyme is overexpressed in prostate cancer, and its levels are associated with patient's metabolic status: Potential value as a non-invasive biomarker. , 2016, Cancer letters.

[18]  K. Nutahara,et al.  Epidermal Growth Factor Receptor Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated with Docetaxel Chemotherapy , 2016, International journal of molecular sciences.

[19]  G. Kristiansen,et al.  PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy , 2016, Oncotarget.

[20]  David S. K. Lu,et al.  Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. , 2016, JAMA oncology.

[21]  L. Dai,et al.  Using Serological Proteome Analysis to Identify Serum Anti‐Nucleophosmin 1 Autoantibody as a Potential Biomarker in European‐American and African‐American Patients With Prostate Cancer , 2016, The Prostate.

[22]  R. Skotheim,et al.  PBX3 is a putative biomarker of aggressive prostate cancer , 2016, International journal of cancer.

[23]  M. Loda,et al.  Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer. , 2016, European urology.

[24]  D. Edwards,et al.  The Germ Cell Gene TDRD1 as an ERG Target Gene and a Novel Prostate Cancer Biomarker , 2016, The Prostate.

[25]  Johannes Stein,et al.  CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients , 2016, Epigenetics.

[26]  M. Rivera,et al.  Branched Chain RNA In Situ Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer , 2016, Clinical Cancer Research.

[27]  M. Liu,et al.  Prostate-Specific G-Protein Coupled Receptor, an Emerging Biomarker Regulating Inflammation and Prostate Cancer Invasion. , 2016, Current molecular medicine.

[28]  L. Dai,et al.  Evaluation and characterization of anti-RalA autoantibody as a potential serum biomarker in human prostate cancer , 2016, Oncotarget.

[29]  K. D. Sørensen,et al.  Large‐scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levels , 2016, Molecular oncology.

[30]  L. Bégin,et al.  SPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: Implications for biomarker development. , 2016, Urologic oncology.

[31]  Ahmedin Jemal,et al.  Annual Report to the Nation on the Status of Cancer, 1975‐2012, featuring the increasing incidence of liver cancer , 2016, Cancer.

[32]  M. Brunelli,et al.  Urine TMPRSS2: ERG Fusion Transcript as a Biomarker for Prostate Cancer: Literature Review. , 2016, Clinical genitourinary cancer.

[33]  G. Kristiansen,et al.  TRPM4 protein expression in prostate cancer: a novel tissue biomarker associated with risk of biochemical recurrence following radical prostatectomy , 2016, Virchows Archiv.

[34]  P. Leedman,et al.  Genetic and cellular studies highlight that A Disintegrin and Metalloproteinase 19 is a protective biomarker in human prostate cancer , 2016, BMC Cancer.

[35]  Xin Lu,et al.  Integration of lipidomics and transcriptomics unravels aberrant lipid metabolism and defines cholesteryl oleate as potential biomarker of prostate cancer , 2016, Scientific Reports.

[36]  J. Osborne,et al.  PVT1 Exon 9: A Potential Biomarker of Aggressive Prostate Cancer? , 2015, International journal of environmental research and public health.

[37]  Chiung-Kuei Huang,et al.  Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer , 2015, Oncotarget.

[38]  H. Klocker,et al.  Is Eotaxin‐1 a serum and urinary biomarker for prostate cancer detection and recurrence? , 2015, The Prostate.

[39]  Wen Cheng,et al.  Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer. , 2015 .

[40]  L. Manzoli,et al.  SOX2 boosts major tumor progression genes in prostate cancer and is a functional biomarker of lymph node metastasis , 2015, Oncotarget.

[41]  Xiao Han,et al.  Identification of specific DNA methylation sites on the Y-chromosome as biomarker in prostate cancer , 2015, Oncotarget.

[42]  R. Singal,et al.  Serum GADD45a methylation is a useful biomarker to distinguish benign vs malignant prostate disease , 2015, British Journal of Cancer.

[43]  G. Guelfi,et al.  Stability Assessment of Candidate Reference Genes in Urine Sediment of Prostate Cancer Patients for miRNA Applications , 2015, Disease markers.

[44]  R. Shah,et al.  Heterogeneity of PTEN and ERG expression in prostate cancer on core needle biopsies: implications for cancer risk stratification and biomarker sampling. , 2015, Human pathology.

[45]  W. Mandecki,et al.  Macrophage Inhibitory Cytokine 1 Biomarker Serum Immunoassay in Combination with PSA Is a More Specific Diagnostic Tool for Detection of Prostate Cancer , 2015, PloS one.

[46]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[47]  W. Fan,et al.  Diagnostic Value of SFRP1 as a Favorable Predictive and Prognostic Biomarker in Patients with Prostate Cancer , 2015, PloS one.

[48]  L. Hansson,et al.  Breast and prostate cancer patients differ significantly in their serum Thymidine kinase 1 (TK1) specific activities compared with those hematological malignancies and blood donors: implications of using serum TK1 as a biomarker , 2015, BMC Cancer.

[49]  O. Coqueret,et al.  Olfactomedin‐4 is a candidate biomarker of solid gastric, colorectal, pancreatic, head and neck, and prostate cancers , 2015, Proteomics. Clinical applications.

[50]  C. Stephan,et al.  Urinary thiosulfate as failed prostate cancer biomarker – an exemplary multicenter re-evaluation study , 2015, Clinical chemistry and laboratory medicine.

[51]  Shun Li,et al.  Serum C-reactive protein acted as a prognostic biomarker for overall survival in metastatic prostate cancer patients , 2015, Tumor Biology.

[52]  P. Jarzemski,et al.  Engrailed-2 protein as a potential urinary prostate cancer biomarker: a comparison study before and after digital rectal examination , 2015, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[53]  B. Yalcin,et al.  Resistance to androgen-pathway drugs in prostate cancer. , 2014, The New England journal of medicine.

[54]  K. Kamoi,et al.  Evaluation of PSF1 as a prognostic biomarker for prostate cancer , 2014, Prostate Cancer and Prostatic Disease.

[55]  J. Hou,et al.  Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer , 2014, Oncotarget.

[56]  Sweta Rani,et al.  miR‐34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression , 2014, The Prostate.

[57]  E. Ranieri,et al.  Pentraxin 3: a novel biomarker for predicting progression from prostatic inflammation to prostate cancer. , 2014, Cancer research.

[58]  H. Shahrokh,et al.  Expression profile of MAGI2 gene as a novel biomarker in combination with major deregulated genes in prostate cancer , 2014, Molecular Biology Reports.

[59]  B. Yao,et al.  Protein Tyrosine Kinase 7 (PTK7) as a Predictor of Lymph Node Metastases and a Novel Prognostic Biomarker in Patients with Prostate Cancer , 2014, International journal of molecular sciences.

[60]  N. Nonomura,et al.  Serum fucosylated haptoglobin as a novel prognostic biomarker predicting high‐Gleason prostate cancer , 2014, The Prostate.

[61]  T. Ahlering,et al.  Urinary nerve growth factor as an oncologic biomarker for prostate cancer aggressiveness. , 2014, Urologic oncology.

[62]  Yinghao Sun,et al.  PPM1D as a novel biomarker for prostate cancer after radical prostatectomy. , 2014, Anticancer research.

[63]  Yuantong Tian,et al.  AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression , 2014, Diagnostic Pathology.

[64]  Hitendra R. H. Patel,et al.  Prostate stem cell antigen – novel biomarker and therapeutic target? , 2014, Expert review of anticancer therapy.

[65]  Pasquale Ditonno,et al.  Spondin-2, a secreted extracellular matrix protein, is a novel diagnostic biomarker for prostate cancer. , 2013, The Journal of urology.

[66]  V. Cheynet,et al.  Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer , 2013, Journal of visualized experiments : JoVE.

[67]  C. Scholz,et al.  MiR-205 Is Progressively Down-Regulated in Lymph Node Metastasis but Fails as a Prognostic Biomarker in High-Risk Prostate Cancer , 2013, International journal of molecular sciences.

[68]  L. Mechelli,et al.  Circulating microRNAs and Kallikreins before and after Radical Prostatectomy: Are They Really Prostate Cancer Markers? , 2013, BioMed research international.

[69]  S. Hilsenbeck,et al.  Semaphorin 4F as a Critical Regulator of Neuroepithelial Interactions and a Biomarker of Aggressive Prostate Cancer , 2013, Clinical Cancer Research.

[70]  M. Rubin,et al.  V-ets erythroblastosis virus E26 oncogene homolog (avian)/Trefoil factor 3/high-molecular-weight cytokeratin triple immunostain: a novel tissue-based biomarker in prostate cancer with potential clinical application. , 2013, Human pathology.

[71]  Yusuke Nakamura,et al.  Plasma low-molecular-weight proteome profiling identified neuropeptide-Y as a prostate cancer biomarker polypeptide. , 2013, Journal of proteome research.

[72]  L. Lessard,et al.  Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancer. , 2013, European journal of cancer.

[73]  R. Kaneva,et al.  Evaluation of the clinical value of the newly identified urine biomarker HIST1H4K for diagnosis and prognosis of prostate cancer in Bulgarian patients. , 2013, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[74]  S. Bhattacharyya,et al.  Arylsulfatase B (N-Acetylgalactosamine-4-Sulfatase): Potential Role as a Biomarker in Prostate Cancer , 2013, Prostate Cancer and Prostatic Diseases.

[75]  M. Gleave,et al.  Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen , 2013, Cancer medicine.

[76]  A. D'Amico,et al.  American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010 , 2010, CA: a cancer journal for clinicians.

[77]  David Chia,et al.  Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.

[78]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[79]  E. Fearon,et al.  Cancer progression , 1999, Current Biology.

[80]  A. Tewari,et al.  The Use of Biomarkers in Prostate Cancer Screening and Treatment. , 2017, Reviews in urology.

[81]  J. López-Guerrero,et al.  PCA3 as a second-line biomarker in a prospective controlled randomized opportunistic prostate cancer screening programme. , 2017, Actas urologicas espanolas.

[82]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[83]  G. Kristiansen,et al.  PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies. , 2017, The Journal of molecular diagnostics : JMD.

[84]  Yuzhuo Wang,et al.  Elevated XPO6 expression as a potential prognostic biomarker for prostate cancer recurrence. , 2016, Frontiers in bioscience.

[85]  A. Ouhtit,et al.  Hoxb13, a potential prognostic biomarker for prostate cancer. , 2016, Frontiers in bioscience.

[86]  T. Dellavedova Prostatic specific antigen. From its early days until becoming a prostate cancer biomarker. , 2016, Archivos espanoles de urologia.

[87]  Kai Zhang,et al.  MicroRNA-21 in peripheral blood mononuclear cells as a novel biomarker in the diagnosis and prognosis of prostate cancer. , 2016, Cancer biomarkers : section A of Disease markers.

[88]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[89]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.